Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease

@article{Nicholson2001CostutilityOE,
  title={Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease},
  author={Tricia Nicholson and Alistair Mcguire and Ruairidh Milne},
  journal={BMC Cardiovascular Disorders},
  year={2001},
  volume={1},
  pages={2 - 2}
}
BACKGROUND Low molecular weight heparins hold several advantages over unfractionated heparin including convenience of administration. Enoxaparin is one such heparin licensed in the UK for use in unstable coronary artery disease (unstable stable angina and non-Q wave myocardial infarction). In these patients, two large randomised controlled trials and their meta-analysis showed small benefits for enoxaparin over unfractionated heparin at 30-43 days and potentially at one year. We found no… CONTINUE READING
7 Citations
21 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Dalteparin and enoxaparin for unstable angina and non-Q-wave myocardial infarction: update

  • T Nicholson, R Milne, K Stein
  • Development and Evaluation Committee Report No
  • 2000
Highly Influential
3 Excerpts

Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease

  • KA Fox, N Bosanquet
  • Br J Cardiol
  • 1998
3 Excerpts

Similar Papers

Loading similar papers…